Release 8 November, 2019: Sienna and VivaZome to Evaluate EXO-NET(tm) for VivaZome’s Exosome-based Therapeutics
Media Release 30 October, 2019: David Haylock, PhD Appointed as Chief Executive Officer
Media Release 27 August 2019: Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.
Media Release 14 August 2019: Dr David Haylock joins VivaZome Therapeutics as Chief Scientific Officer; Manufacturing development work begins at CSIRO.
Media Release 18 December 2017: $2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy